Moderna skyrocketed 245% since it announced its COVID-19 vaccine candidate mRNA-1273 on Feb 10. The solid run is likely to continue as most of the analysts are optimistic on the stock.
Moderna plans to begin the Phase 3 study of mRNA-1273 this month.
Moderna shares have surged more than 280% so far this year on the positive development of coronavirus vaccine.
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.
These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.
Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.
Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.
An oil collapse sent Wall Street into a tailspin on Mar 9, indicating that the 11-year-long bull market might soon end. These ETFs may, however, survive the crash.
These sector ETFs gained or lost the least in the coronavirus-induced rout in February.
Can biotech ETFs repeat its success story of 2019 in the election year of 2020?
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.